FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

Microorganisms

Fortunatus C. Ezebuo¹  Ikemefuna C. Uzochukwu¹  James J. Valdes²  Michal Stefanik²  Ludek Eyer²  Jan Haviernik²  Martina Fojtikova²  Jiri Salat²  Daniel Ruzek² 

[1] Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, PMB 5025 Awka 420281, Nigeria;Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic;

关键词: FDA;    flavivirus;    Zika virus;    tick-borne encephalitis virus;    West Nile virus;    antiviral;   

DOI  :  10.3390/microorganisms8040599

来源: DOAJ

【 摘 要 】

Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors.

【 授权许可】

Unknown